Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023
26 April 2023 - 10:30PM
Business Wire
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”,
Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines
company focused on the development of infectious disease vaccines
and significant opportunities within liver and respiratory rare
diseases, today announced that it will release its financial
results for the quarter ended March 31, 2023 after the market close
on Tuesday, May 9 and will also host a conference call and webcast
at 4:30 pm Eastern Time on May 9, 2023.
Arcturus Therapeutics First Quarter 2023 Earnings Conference
Call
- Tuesday, May 9, 2023 @ 4:30 p.m. ET
- Domestic: 1-888-886-7786
- International: 1-416-764-8658
- Conference ID: 70942720
- Webcast: Link
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus
Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage
clinical mRNA medicines and vaccines company with enabling
technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA
Technology (samRNA) and (iii) mRNA drug substance along with drug
product manufacturing expertise. Arcturus’ pipeline includes RNA
therapeutic candidates to potentially treat ornithine
transcarbamylase (OTC) deficiency and cystic fibrosis, along with
its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and
influenza. Arcturus’ versatile RNA therapeutics platforms can be
applied toward multiple types of nucleic acid medicines including
messenger RNA, small interfering RNA, circular RNA, antisense RNA,
self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’
technologies are covered by its extensive patent portfolio (patents
and patent applications issued in the U.S., Europe, Japan, China,
and other countries). For more information, visit
www.ArcturusRx.com. In addition, please connect with us on Twitter
and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230426005037/en/
IR and Media Contacts Arcturus Therapeutics Neda
Safarzadeh VP, Head of IR/PR/Marketing (858) 900-2682
IR@arcturusrx.com Kendall Investor Relations Carlo Tanzi, Ph.D.
(617) 914-0008 ctanzi@kendallir.com
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From Apr 2024 to May 2024
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From May 2023 to May 2024